Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009614
Filing Date
2023-05-12
Accepted
2023-05-12 16:46:42
Documents
57
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fencf-20230331x10q.htm   iXBRL 10-Q 1238659
2 EX-31.1 fencf-20230331xex31d1.htm EX-31.1 13953
3 EX-31.2 fencf-20230331xex31d2.htm EX-31.2 18464
4 EX-32.1 fencf-20230331xex32d1.htm EX-32.1 9362
5 EX-99.1 fencf-20230331xex99d1.htm EX-99.1 200127
6 GRAPHIC fencf-20230331xex99d1001.jpg GRAPHIC 3171
  Complete submission text file 0001558370-23-009614.txt   6049511

Data Files

Seq Description Document Type Size
7 EX-101.SCH fencf-20230331.xsd EX-101.SCH 46061
8 EX-101.CAL fencf-20230331_cal.xml EX-101.CAL 32985
9 EX-101.DEF fencf-20230331_def.xml EX-101.DEF 201910
10 EX-101.LAB fencf-20230331_lab.xml EX-101.LAB 299231
11 EX-101.PRE fencf-20230331_pre.xml EX-101.PRE 293346
51 EXTRACTED XBRL INSTANCE DOCUMENT fencf-20230331x10q_htm.xml XML 1065337
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Filer) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-32295 | Film No.: 23916640
SIC: 2836 Biological Products, (No Diagnostic Substances)